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Clinical and neurophysiological 
investigation of a large family with 
dominant Charcot-Marie-Tooth type 
2 disease with pyramidal signs 
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ABSTRACT
Charcot-Marie-Tooth (CMT) disease is a hereditary neuropathy of motor and sensory 
impairment with distal predominance. Atrophy and weakness of lower limbs are the first 
signs of the disease. It can be classified, with the aid of electromyography and nerve 
conduction studies, as demyelinating (CMT1) or axonal (CMT2). Objective: Clinical and 
neurophysiological investigation of a large multigenerational family with CMT2 with 
autosomal dominant mode of transmission. Method: Fifty individuals were evaluated 
and neurophysiological studies performed in 22 patients. Results: Thirty individuals had 
clinical signs of motor-sensory neuropathy. Babinski sign was present in 14 individuals. 
Neurophysiological study showed motor-sensory axonal polyneuropathy. Conclusion: 
The clinical and neurophysiological characteristics of this family does not differ from those 
observed with other forms of CMT, except for the high prevalence of Babinski sign.
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Investigação clínica e neurofisiológica de família com doença de Charcot-Marie-Tooth 
tipo 2 com sinais piramidais
RESUMO
A doença de Charcot-Marie-Tooth (CMT) é uma neuropatia hereditária de acometimento 
sensitivo e motor de predomínio distal. Atrofia e fraqueza em membros inferiores são os 
primeiros sinais da doença. Pode ser classificada, com auxílio da eletroneuromiografia, em 
desmielinizante (CMT1) ou axonal (CMT2). Objetivo: Investigação clínica e neurofisiológica 
de família com portadores de CMT2 de herança dominante. Método: Foi feita avaliação 
neurológica de 50 indivíduos e eletroneuromiografia em 22 pacientes. Resultados: Trinta 
indivíduos tinham sinais clínicos de neuropatia sensitivo-motora. Sinal de Babinski estava 
presente em 14 indivíduos. A eletroneuromiografia demonstrou polineuropatia axonal 
sensitiva e motora. Conclusão: As características clínicas e neurofisiológicas desta família 
não se diferem das observadas em outras formas de CMT, exceto pela alta prevalência 
de sinal de Babinski. 
Palavras-chave: doença de Charcot-Marie-Tooth, CMT2, neuropatia hereditária axonal. 
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Charcot-Marie-Tooth (CMT) disease 
is one of the most common genetically de-
termined neurological disorder, with an 
estimated prevalence of 37/100,000 indi-
viduals1. It is characterized by impairment 
of peripheral nerves function, with distal 
predominance and a highly variable clin-
ical course.
According to the nature of periph-
eral nerve injury, CMT disease can be 
divided into two main groups: demye-
linating (CMT1) and axonal (CMT2)2,3. 
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Other classifications are based on transmission pattern 
and genetic basis. 
CMT disease causes progressive weakness and at-
rophy, initially in distal muscles of lower limbs and later 
reaching the upper limbs, with foot deformities, loss of 
sensitivity, and reduced tendon reflexes3. 
Especially among individuals affected by demyelin-
ating neuropathy (CMT1), it is frequent to find atrophy 
of the distal third of the legs, giving the appearance of 
an inverted champagne glass and of pes cavus. The prox-
imal muscles are rarely affected3. Cranial nerve involve-
ment is rare, but there are descriptions of families with 
vocal cord paresis and deafness associated with CMT4,5. 
Reduction and even abolition of the reflexes are the rule, 
although in some forms of CMT it is possible to find 
brisk reflexes and even the presence of Babinski sign3,4,6-8.
It is not common for individuals with CMT to 
present subjective sensory symptoms or neuropathic 
pain9. The sensory abnormalities are primarily due to a 
more pronounced loss of myelinated thick fibers (Aα)1. 
Sense for vibration and pain are the first to be changed.
More rarely, additional signs can be found such as ac-
tion tremor, optic atrophy, deafness, pupillary abnormal-
ities, and foot ulcers4,10. In some individuals and families, 
pyramidal signs, as brisk tendon reflexes and Babinski 
sign, without spasticity, might be detected3,4,8,10. 
Electromyography (EMG) and nerve conduction 
studies (NCS) allow differentiation of demyelinating 
(CMT1) from axonal (CMT2) neuropathies: in the first, 
the conduction velocity is less than 38 m/s, while in the 
second it is over 38 m/s2,3,11-14. There are also interme-
diate forms, with motor conduction velocities of the me-
dian between 30 and 40 m/s15.
According to the type of inheritance, CMT 1 is of au-
tosomal dominant inheritance, and CMT2 is transmitted 
as a dominant or recessive character1,4,16. The forms of 
inheritance linked to the X are known as CMTX, and 
the autosomal-recessive demyelinating forms are called 
CMT4. CMT5 is used to refer to CMT with spasticity.
For CMT1, five loci and the genes associated with 
them have been located and identified: about 70 to 80% 
of cases are caused by duplication of the PMP22 gene, 
and 5 to 10% are caused by mutation in the MPZ gene1. 
To date, 13 loci are known to be associated with 
CMT2, and only 9 genes have been identified so far4,17. 
Four of the 13 loci are related to forms of recessive in-
heritance and some have been identified in only one 
family. CMT 2A is the most prevalent form of axonal 
CMT, being responsible for approximately 20% of ax-
onal CMT17. It is caused by mutation of the MFN2 gene, 
located on the 1p36 chromosome, which encodes the 
GTPase mitofusin, involved in mitochondrial fusion4,17. 
This study aims to investigate, from the clinical, neu-
rophysiological, and genetic point of view, a family living 
in the municipality of Tobias Barreto, situated 180 km 
from Aracaju, Sergipe State, Brazil. 
METHOD
Clinical evaluation
After completion of the heredogram and identifi-
cation of possible individuals affected by CMT among 
family members, a clinical neurological evaluation was 
performed. All participants of the study signed a con-
sent form, approved by the Institutional Committee for 
Ethics in Research.
Neurophysiological studies
EMG was performed using Viking Quest (Nicolet) 
9.0 equipment. The records were obtained following a 
conventional protocol as reported by Oh and cols.18, sur-
face electrodes and stimulator were used for NCS. The 
action potentials amplitudes for motor nerves were mea-
sured from the peak of the negative wave to the baseline, 
and for sensory nerves from peak-to-peak. Temperature 
were controlled, and never less than 33°C. 
Application of the Charcot-Marie-Tooth  
Neuropathy Score 
The Charcot-Marie-Tooth Neuropathy Score 
(CMTNS), developed by Shy and cols.19 were used to as-
sess disease severity. This score combines motor and sen-
sory manifestations with data obtained from NCS. The 
maximum possible score is of 36 points and patients with 
less than 10 points are classified as mildly affected, with 
between 11 and 20 points as moderately compromised 
and with more than 21 points as severely affected19.
RESULTS
Thirth-five individuals with CMT were recognized, 
and 30 completed clinical evaluation which allows in-
clusion in this study. Age at ascertainment varied from 
3 to 75 years, and age of onset varied greatly. Four pa-
tients with abnormal findings at clinical examination did 
not have complaints. Frequent falls was the the first rec-
ognized abnormality in cases with onset at childhood. 
In adolescents and adults, inability to run was usually 
seen as an early manifestation. Neuropathic pain was 
never reported. 
This family presents a form of CMT with auto-
somal dominant transmission, as can be observed in the 
heredogram (Figure). The presence of father-to-child 
transmission excludes an X-linked transmission.
Neurological exam – The clinical findings are sum-
marized in Table 1. All the patients were able to walk 
without assistance, except patients III-10 and III-41, who 
already had significant impairment of gait and could only 
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Table 1. Clinical data of CMT2 family.
Patient
Age 
(years)
Onset 
(years) Ambulation Atrophy Pes cavus
Babinski 
sign
Tibialis anterior 
weakness
Achilles 
reflex Sensitivity*
II-2 75 40 yes no no  no present reduced
II-14 74 53 yes legs and hands yes  yes absent reduced
III-9 46 14 yes hands and legs yes  yes absent reduced
III-10 48 12 no legs and hands no bilateral yes exalted reduced
III-12 51 10 yes hands and feet no  yes absent reduced
III-14 36 14 yes forearms and legs yes yes present reduced
III-25 47 30 yes hands and feet no  yes present reduced
III-35 41 30 yes hands and feet no bilateral yes present reduced
III-39 44 16 yes legs yes  yes absent reduced
III-41 45 7 with aid legs and hands yes yes absent reduced
III-49 43 37 yes no no  yes present reduced
III-51 37 5 yes no yes  yes brisk reduced
IV-1 23 15 yes no yes  yes present reduced
IV-5 18 13 yes hands and legs yes bilateral yes absent reduced
IV-8 28 9 yes legs yes  yes absent reduced
IV-13 13 5 yes feet and hands yes bilateral yes absent reduced
IV-14 12 7 yes legs and hands no right yes absent reduced
IV -18 19 19 yes no yes right yes present reduced
IV-20 13 8 yes hands and legs yes bilateral yes present reduced
IV-31 11 9 yes legs yes  yes absent reduced
IV-32 16 10 yes legs yes bilateral yes present reduced
IV-39 7 6 yes hands and feet yes left yes present reduced
IV-44 11 6 yes legs and hands yes bilateral yes brisk reduced
IV-50 13 6 yes legs and hands yes bilateral yes brisk reduced
IV-52 11 8 yes legs and hands yes bilateral yes absent reduced
IV- 54 20 7 yes feet and hands yes yes absent reduced
IV-57 14 12 yes hands and feet yes right yes present reduced
IV-59 10 5 yes hands and feet yes left yes present reduced
V- 3 6 3 yes no no  no absent
V-4 3 3 yes no no  yes present
TA: tibialis anterior; CMT2: Charcot-Marie-Tooth type 2; *Sensitivity surface-painful (pinprick) and deep-vibration.
Figure. Heredogram of family with CMT 2.
Filled symbols: affected individuals; Open symbols: unaffected individuals; Squares: men; Circles: woman; 
Shaded symbols: probably affected; Slashed symbols: deceased individuals; CMT2: Charcot-Marie-Tooth type 2.
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Table 2. Neurophysiological data of patients with CMT 2.
Patient Age Side R/L
Median 
motor
amp. / CV
Ulnar 
motor
amp. / CV
Peroneal 
motor
amp. / CV
Tibialis 
motor
amp. / CV
Median 
sensory
amp. / CV
Ulnar 
sensory
amp. / CV
Sural 
sensory
amp. / CV
Wave-F 
ulnar
II-14 73 D
E
Unrecor.
Unrecor.
3.7 / 56 Unrecor.
Unrecor.
Unrecor.
Unrecor.
6.1 / 48 NO
NO
NO
NO
28.9
 
III-14 36 D
E
1.2 / 58 Unrecor. 
Unrecor.
Unrecor.
Unrecor.
4 / 51 4.0 / 47
3.0 / 43
 
 
III-25 47 D
E
Unrecor. 5.0 / 51 1.5 / 45
0.4 / 37
1.1 / 47
0.9 / 49
13 / 54 NO 4.0 / 45
3.0 / 51
29.8
 
III-35 41 D
E
1.1 / 50 1.4 / 49
0.6 / 52
5.7 / 41
2.4 / 48
33 / 61 3.0 / 48
3.0 / 44
 
 
III-41 41 D
E
Unrecor.
Unrecor.
1.8 / 52
2.7 / 39
Unrecor.
Unrecor.
Unrecor.
Unrecor.
14 / 53
26 / 52
7.0 / 56
9.0 / 57
2.0 / 46
2.0 / 42
30.3 
 
III-49 43 D
E
6.5 / 53 8.2 / 61 3.6 / 36
3.8 / 34
5.1 / 46
4.5 / 44
18 / 54 4.0 / 44
NO
 
 
IV-5 18 D
E
Unrecor. 7.2 / 58 0.9 / 35
0.2 / 32
1.5 / 37
0.9 / 43
4.0 / 58 NO
NO
 
 
IV-8 28 D
E
Unrecor.
Unrecor.
0.4 / 46 Unrecor.
Unrecor.
Unrecor.
Unrecor.
NO
NO
2.5 / 43
2.6 / 39
 
 
IV-13 13 D
E
Unrecor 0.2 / 46 0.6 / 43
0.9 / 41
0.3 / 49
0.3 / 37
NO NO 2.3 / 44
2.6 / 49
 
 
IV-14 12 D
E
0.2 / 46 0.8 / 47
0.1 / 45
1.5 / 49
2.1 / 41
NO 3.6 / 45
3.0 / 52
 
 
IV-18 19 D
E
9.9 / 56 2.1 / 45
1.4 / 40
11.1 / 50
15.1 / 51
12 / 53 7 / 47 7.0 / 47
8.0 / 46
 
 
IV-20 13 D
E
0.2 /
2.6 / 50
2.4 / 54 4.2 / 45
3.0 / 45
4.0 / 43
5.5 / 43
43 / 50 36 / 61 2.4 / 40
1.5 / 40
32.8
31.8
IV-31 11 D
E
4.3 / 53 2.1 / 45
2.1 / 44
12.2 / 48
10.0 / 48
7.0 / 46
4.6 / 50
 
 
IV-32 15 D
E
1.9 / 46
1.7 / 49
7.5 / 43
8.2 / 41
10.2 / 47
9.6 / 42
 
IV-39 7 D
E
5.8 / 58 3.1 / 52
4.1 / 48
6.2 / 47
7.4 / 58
20 / 52 14.0 / 50
12.0 / 44
IV-44 16 D 
E
Unrecor. Unrecor. 2.0 / 40 
Unrecor.
2.2 / 45
3.3 / 45
1.9 / 47 6.0 / 53
4.0 / 48
IV-50 12 D
E
3.6 / 56 1.2 / 37
2.5 / 44
6.8 / 40
6.6 / 45
NO 23 / 53 13.0 / 43
12.1 / 43
IV-52 10 D
E
1.3 / 40
1.2 / 40
2.3 / 42
1.9 / 40
5.1 / 42
6.2 / 43
IV-54 20 D
E
2.0 / 52 0.1 / 37
Unrecor.
3.0 / 39
1.3 / 38
29 / 48 20 / 48 8.0 / 42
7.0 / 42
IV-57 14 D
E
0.2 / 53 1.9 / 63 Unrecor
0.6 / 37
4.5 / 43
2.4 / 36
11 / 54 6.0 / 50
8.0 / 47
IV-59 9 D
E
5.1 / 51 1.4 / 42
1.6 / 40
9.4 / 48
9.1 / 46
5.4 / 41
5.6 / 40
V-3
 
6 D
E
  
 
1.9 / 45
2.1/ 41
10.2 / 43
10.8 / 43
 8.0 / 50
8.2 / 50
Reference values: Dumitru, 199511. Amp.: amplitude; VC: velocity of conduction; L: left; R: right; NO: not obtained; Unrecord.: unrecordable; CMT 2: Charcot-
Marie-Tooth type 2. Abnormal values in bold.
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ambulate with an walker. The siblings IV-13 and IV-14 
had a very unstable gait, but could walk without assis-
tance; they are nephews of patient III-10, and all affect 
individuals in this branch of the kindred had a more se-
vere form of CMT, associated with pyramidal signs. 
Pyramidal signs, characterized by the presence of 
Babinski sign with or without brisk reflexes, was present 
in 14 patients. None of the subjects presented spasticity. 
Lower limbs atrophy was seen in 23 patients (76%) and 
hands atrophy in 19 individuals (63%). The atrophy was 
restricted to the distal third of the legs and to the hands, 
except for patients III-10, III-14, IV-8, IV-44, IV-52, IV-
57, and II-14, who also had forearm atrophy , and pa-
tients IV-13 and IV-14, who had forearms and arms at-
rophy. Pes cavus was present in 21 patients (70%) and flat 
feet were observed in six individuals. Paresis of the tibi-
alis anterior was the most consistent clinical abnormality, 
present in 28 patients (93%). In all patients, with excep-
tion of individuals V-4 and V-3, who where too young 
to give consistent answers, a reduction of superficial and 
deep sensitivity in the distal portions of the lower limbs 
were detected. Pain and vibration hypoesthesia were also 
detected in fingers of 10 patients. Thirteen individual had 
bilateral abolition of the Achilles reflexes and four pa-
tients (IV-44, III- 51, IV-50, and III-10) presented brisk 
reflexes. Seven patients (IV-13, IV-14, IV-44, IV-5, IV-57, 
III-14, and III-10) had brisk patellar reflexes . 
Neurophysiological studies – EMG and NCS were 
performed in 22 individuals and the data obtained are 
summarized in Table 2. All 22 patients had neurophys-
iological changes consistent with predominantly motor 
axonal neuropathy and greater distal involvement, except 
for patient IV-39. The most consistent neurophysiolog-
ical finding was reduced amplitudes of compound motor 
action potentials of the motor nerves (CMAPs). The pe-
roneal nerves showed the greatest reductions in CMAPs. 
Motor conduction velocity was slightly reduced in only 
10 of the 22 patients. The lowest conduction velocity 
of the median nerve was 46 m/s. In the study of sen-
sory conduction, a reduction of the amplitudes of sen-
sory nerve action potentials (SNAPs) was also the most 
common finding, especially in the sural nerves. EMG 
with concentric needle proved to be abnormal in the 12 
patients in which it was performed. The most consis-
tent finding was reduction in the recruitment pattern of 
motor units, seen in the short extensor muscles of the 
fingers and tibialis anterior. 
CMTNS application – The CMTNS was applied in 
21 patients and results can be seen in Tables 3 and 4. The 
Table 3. Charcot-Marie-Tooth Neuropathy Score in 21 patients 
with CMT2.
Patient Age Score
Duration of 
disease (years)
II-14 75 18 35
III-10 48 26 36
III-14 36 22 22
III-25 47 16 17
III-35 41 12 11
III-41 45 21 37
III-49 43 6 6
IV-5 18 13 5
IV-8 28 16 19
IV-13 13 25 8
IV-14 12 23 5
IV-18 19 11 Not known
IV-20 13 12 5
IV-32 16 9 6
IV-39 7 6 1
IV-44 11 17 5
IV-50 13 11 7
IV-52 11 14 3
IV-54 20 10 13
IV-57 14 14 2
IV-59 10 9 5
Mean age: 25.6 years; Average score: 14.8 points; CMT 2: Charcot-Marie-
Tooth type 2.
Table 4. Disease duration and Charcot-Marie-Tooth Neuropathy Score.
 Generation II Generation III Generation IV Gereration V
Number of patients 2 10 16 2
Mean age 43.33 years 14.63 years
Age range 36 to 48 years 7 to 28 years
Mean age of onset 46.5 years 17.5 years 9.06 years 3 years
Range of age of onset 40 to 50 years 5 to 37 years 5 to 19 years 3 years 
Mean duration of disase 21.5 years 7 years
CMTNS mean 17.16 13.91
CMTNS range 6 to 26 6 to 25
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patients showed variation from 6 to 26 points. Five were 
mildly affected (score up to 10), 11 were moderately com-
promised (score between 11 and 20), and five had a severe 
compromise (score >21). The mean score in generation 
III was 17.16 points (range 6 to 26 points). In genera-
tion IV, the mean was 13.9 points (range 6 to 25 points). 
DISCUSSION
In the last two decades several loci and genes related 
to CMT2 have been recognized20. We conducted a clin-
ical and neurophysiological study of a multigenerational 
family with 35 individuals affected by an autosomal dom-
inant form of CMT2, which is probably the largest kin-
dred ever reported in Brazil. 
Thirty individuals with CMT from completed the 
clinical study. We observed an earlier onset and larger 
severity of the disease at later generations, a fact already 
observed by other authors21-23. Assessment of disease se-
verity by CMTNS shows that ten individuals of genera-
tion IV already have high scores. Generation IV, with a 
mean of 7 years of disease, has in the CMTNS a mean of 
13.9 points (moderate incapacity). In generation III, with 
a mean of 21.5 years of disease, CMTNS mean scorer 
was of 17.1 points. This finding could be a result of an 
ascertainment bias, caused by an increased awareness 
about the disease. The assessment of individuals of gen-
erations V and VI might help establish this issue.
Neuropathic pain and other positive sensory symp-
toms have not been fully investigated in most families 
studies of CMT1. Germignani et al.9, showed that ap-
proximately 71% of the individuals had positive sensory 
symptoms, including neuropathic pain. In contrary, none 
of the individuals evaluated in this family complained 
of neuropathic pain. When present, sensory complaints 
were most often consistent with late onset nociceptive 
pain, and probably arising from osteo-muscular defor-
mities. as suggested by Padua et al.24.
Trophic changes seen in the feet, legs, and hands of 
individuals from this family are typical of CMT disease. 
The presence of pes cavus, so characteristic of CMT dis-
ease, was absent in one-third of the patients. 
In some individuals, tendon reflexes were abolished 
and in others were brisk. The presence of pyramidal 
signs, with Babinski sign and hyperreflexia seen in sev-
eral individuals of this family, has been described in other 
families with CMT3,8,25,26. What differentiates CMT2 with 
pyramidal signs from CMT V (or HMSN V) is the ob-
ligate presence of spasticity in the latter. Vucci et cols. 
found CMT with pyramidal signs in 9% of the families 
that they have studied, and demonstrated that the pres-
ence of CMT with Babinski sign was genetically distinct 
from all known forms of CMT226. In the present family, 
we observed pyramidal signs in 46 % of the individuals. 
Those individual had usually higher scores at CMTNS, 
which could not be explained by central nervous system 
involvement , but probably by a more marked progres-
sion of atrophy, affecting proximal muscles of the upper 
and lower limbs. 
The neurophysiological study was consistent with an 
axonal motor-sensory neuropathy. Reduction of the am-
plitudes of motor action potentials in peroneal nerves 
was the earlier and more frequent finding. This study 
showed no singularities when compared to other fami-
lies with CMT2, but provided information allowed de-
termination of CMTNS, which allowed rating severity 
of disease. The CMTNS seeks to assess precisely the ax-
onal loss that the disease eventually determines over time 
in both the distal and proximal upper and lower limbs.. 
The application of the score is fast and able to be held in 
all locations where the clinical neurological evaluation 
and neuroconduction study can be done, with no need 
for more sophisticated equipment, such as quantitative 
sensory testing (QST). 
To conclude, in this study, we studied 30 individuals 
of a multigenerational family with autosomal dominant 
CMT2, which was associated in 46 % of cases with py-
ramidal signs. Neurophysiological study was typical of 
an axonal compromise. It was also remarkable that dis-
ease severity was higher and age of symptoms onset ear-
lier in the more recent generation. A genetic study is un-
derway to better characterize the molecular basis of this 
condition.
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